{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:37:50Z","timestamp":1793036270746,"version":"4.5.0"},"reference-count":20,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,10,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Histone deacetylase inhibitors (HDACi) are active agents for peripheral T-cell lymphoma (PTCL). Anecdotally angioimmunoblastic T-cell lymphoma (AITL) appears to respond better than PTCL\u2013not otherwise specified (NOS) to HDACi. The new World Health Organization classification shows that a subgroup of PTCL carries similarities in phenotype and gene expression profiling to AITL, comparable to T follicular helper (TFH) cells. The disease might behave similarly to AITL when treated with HDACi. We analyzed 127 patients with AITL or PTCL-NOS treated with HDACi at relapse as a single agent or in combination. We re-reviewed the pathology of all PTCL-NOS to identify the TFH phenotype. Patients received HDACi at relapse as a single agent in 97 cases (76%, 59 TFH, 38 non-TFH) or in combination in 30 cases (24%, 18 TFH, 12 non-TFH) including duvelisib, lenalidomide, lenalidomide plus carfilzomib, and pralatrexate. Seven PTCL-NOS had TFH phenotype; 2 PTCL-NOS were reclassified as AITL. Overall response rate (ORR) was 56.5% (28.9% complete response [CR]) in TFH and 29.4% (19.6% CR) in non-TFH phenotype patients (P = .0035), with TFH phenotype being an independent predictor of ORR (P = .009). Sixteen patients sufficiently responded to HDACi or HDACi in combination with another agent to proceed directly to allogeneic transplantation; 1 of 16 responded to donor lymphocyte infusion (12 TFH, 4 non-TFH). Our results, although retrospective, support that HDACi, as a single agent or in combination, may have superior activity in TFH-PTCL compared with non-TFH PTCL. This differential efficacy could help inform subtype-specific therapy and guide interpretation of HDACi trials.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020002396","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T19:49:55Z","timestamp":1601495395000},"page":"4640-4647","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":100,"title":["T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed\/refractory peripheral T-cell lymphoma"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6986-7954","authenticated-orcid":false,"given":"Paola","family":"Ghione","sequence":"first","affiliation":[{"name":"Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Lymphoma and Myeloma Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Promie","family":"Faruque","sequence":"additional","affiliation":[{"name":"Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5744-0670","authenticated-orcid":false,"given":"Neha","family":"Mehta-Shah","sequence":"additional","affiliation":[{"name":"Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Department of Hematology and Oncology, Washington University School of Medicine, St. Louis, MO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatraman","family":"Seshan","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neval","family":"Ozkaya","sequence":"additional","affiliation":[{"name":"Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakthi","family":"Bhaskar","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Washington University School of Medicine, St. Louis, MO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Yeung","sequence":"additional","affiliation":[{"name":"Hematology Department, Concord Hospital, University of Sydney, Sydney, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Spinner","sequence":"additional","affiliation":[{"name":"Department of Oncology, Stanford University, Stanford CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Lunning","sequence":"additional","affiliation":[{"name":"Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5566-0864","authenticated-orcid":false,"given":"Giorgio","family":"Inghirami","sequence":"additional","affiliation":[{"name":"Department of Medicine, Weill Cornell Medicine, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Moskowitz","sequence":"additional","affiliation":[{"name":"Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Galasso","sequence":"additional","affiliation":[{"name":"Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nivetha","family":"Ganesan","sequence":"additional","affiliation":[{"name":"Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6655-9876","authenticated-orcid":false,"given":"Carrie","family":"van der Weyden","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine, Peter MacCallum Cancer Center, Parkville, Australia; and"},{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Ruan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Weill Cornell Medicine, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0058-2448","authenticated-orcid":false,"given":"H. Miles","family":"Prince","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine, Peter MacCallum Cancer Center, Parkville, Australia; and"},{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8009-4593","authenticated-orcid":false,"given":"Judith","family":"Trotman","sequence":"additional","affiliation":[{"name":"Hematology Department, Concord Hospital, University of Sydney, Sydney, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana","family":"Advani","sequence":"additional","affiliation":[{"name":"Department of Oncology, Stanford University, Stanford CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6576-5256","authenticated-orcid":false,"given":"Ahmet","family":"Dogan","sequence":"additional","affiliation":[{"name":"Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Horwitz","sequence":"additional","affiliation":[{"name":"Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,9,30]]},"reference":[{"issue":"22","key":"2020093012564938000_B1","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1182\/blood.V128.22.4150.4150","article-title":"Differential outcome of patients with primary refractory vs. relapsed peripheral T-cell lymphoma: analysis from a prospective multicenter US cohort study","volume":"128","author":"Lansigan","year":"2016","journal-title":"Blood"},{"key":"2020093012564938000_B2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/hematology.2019000012","article-title":"Emerging strategies in peripheral T-cell lymphoma","volume":"2019","author":"Mehta-Shah","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2020093012564938000_B3","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13045-016-0243-8","article-title":"Romidepsin for the treatment of relapsed\/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial","volume":"9","author":"Foss","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"23","key":"2020093012564938000_B4","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O\u2019Connor","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020093012564938000_B5","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"issue":"20","key":"2020093012564938000_B6","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"24","key":"2020093012564938000_B7","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/blood.2019000779","article-title":"Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry","volume":"134","author":"Amador","year":"2019","journal-title":"Blood"},{"key":"2020093012564938000_B8","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1007\/s10637-010-9596-y","article-title":"Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect","volume":"Suppl 1","author":"Dickinson","year":"2010","journal-title":"Invest New Drugs"},{"issue":"4","key":"2020093012564938000_B9","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/hon.2320","article-title":"Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma","volume":"35","author":"Pro","year":"2017","journal-title":"Hematol Oncol"},{"key":"2020093012564938000_B10","doi-asserted-by":"crossref","first-page":"Abstract 683","DOI":"10.1182\/blood-2018-99-115241","article-title":"The combination of duvelisib, a PI3K-\u03b4,\u03b3 inhibitor, and romidepsin is highly active in relapsed\/refractory peripheral T-cell lymphoma with low rates of transaminitis: results of parallel multicenter, phase 1 combination studies with expansion cohorts [abstract]","volume":"132","author":"Horwitz","year":"2018","journal-title":"Blood"},{"issue":"17","key":"2020093012564938000_B11","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood.2019001285","article-title":"Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study","volume":"134","author":"O\u2019Connor","year":"2019","journal-title":"Blood"},{"key":"2020093012564938000_B12","author":"Mehta-Shah","year":"2017"},{"issue":"22","key":"2020093012564938000_B13","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1182\/blood.V128.22.2991.2991","article-title":"A phase Ib\/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed\/refractory lymphoma shows complete responses in relapsed and refractory T-cell lymphomas","volume":"128","author":"Mehta-Shah","year":"2016","journal-title":"Blood"},{"issue":"17","key":"2020093012564938000_B14","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood.2019001285","article-title":"Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study","volume":"134","author":"O\u2019Connor","year":"2019","journal-title":"Blood"},{"issue":"27","key":"2020093012564938000_B15","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020093012564938000_B16","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2017-09-806737","article-title":"A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma","volume":"131","author":"Amengual","year":"2018","journal-title":"Blood"},{"issue":"3","key":"2020093012564938000_B17","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial Sloan Kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology","volume":"17","author":"Cheng","year":"2015","journal-title":"J Mol Diagn"},{"issue":"5","key":"2020093012564938000_B18","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"2020093012564938000_B19","doi-asserted-by":"crossref","first-page":"Abstract 999","DOI":"10.1182\/blood-2018-99-110354","article-title":"Lenalidomide in combination with CHOP in patients with angioimmunoblastic T-cell lymphoma (AITL): final analysis of clinical and molecular data of a phase 2 lysa study [abstract]","volume":"132","author":"Lemonnier","year":"2018","journal-title":"Blood"},{"issue":"12","key":"2020093012564938000_B20","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1038\/nm.4210","article-title":"DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling","volume":"22","author":"Guryanova","year":"2016","journal-title":"Nat Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/19\/4640\/1760094\/advancesadv2020002396.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/19\/4640\/1760094\/advancesadv2020002396.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T19:50:02Z","timestamp":1601495402000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/19\/4640\/463988\/T-follicular-helper-phenotype-predicts-response-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,30]]},"references-count":20,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2020,10,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020002396","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,30]]}}}